L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumours, well‐differentiated papillary mesothelial tumours and malignant mesotheliomas

Karpathiou, Georgia; Casteillo, François; Dridi, Maroa; Papoudou‐Bai, Alexandra; Dumollard, Jean Marc; Péoc’h, Michel

doi:10.1111/his.14387

Cited by 4 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BAP-1 nuclear expression loss is seen in 50% to 76% of cases of PeM,13,42,61–65 whereas complete MTAP cytoplasmic loss has been reported in 17% of PeM 61. In addition, L1 cell adhesion molecule (L1CAM) expression has not been reported in PeM66,67 whereas the expression of this immunomarker is seen in a subset of ATs and WDPMTs 67…”

Section: Pathologymentioning

confidence: 99%

“…14A-C). Immunohistochemically, WDPMT may be positive for L1CAM (membranous staining seen in 42.8% to 90% of the cases, sometimes only focal) 67,81 and shows a retained expression of BAP-1 whereas it has no CDKN2A deletion by FISH. 86 Furthermore, WDPMT has a molecular profile that is, for the most part, different from the one seen in PeM, including alterations in the following genes: EHD1, ATM, FBXO10, SH2D2A, CHD5, MAGED1, TP73, 86 and CDC42.…”

Section: Well-differentiated Papillary Mesothelial Tumormentioning

confidence: 99%

“…Although reports of AT arising in the peritoneumeven involving multiple sites-have been published, [87][88][89] extreme caution must be exerted when making this diagnosis as both diffuse and localized PeM can mimic AT. 39,45 Immunohistochemically, AT is positive for L1CAM (72.2% to 100%, it can be only focal) 67,80 and shows retained expression of BAP-1 and MTAP. 80 In situ hybridization for CDKN2A and NF2 shows no deletions or losses, 44,45 and molecular studies have shown TRAF7 mutations in 84% to 100% of ATs.…”

Section: Adenomatoid Tumormentioning

confidence: 99%

“…60 BAP-1 nuclear expression loss is seen in 50% to 76% of cases of PeM, 13,42,[61][62][63][64][65] whereas complete MTAP cytoplasmic loss has been reported in 17% of PeM. 61 In addition, L1 cell adhesion molecule (L1CAM) expression has not been reported in PeM 66,67 whereas the expression of this immunomarker is seen in a subset of ATs and WDPMTs. 67 Emerging Markers to Distinguish Peritoneal Mesothelioma From Reactive Mesothelial Hyperplasia Loss of 5-hydroxymethylcytosine (5-hmC) in > 50% of tumor nuclei has been found in 58% of PeMs (surgical specimens, unpublished series).…”

Section: Immunohistochemical Featuresmentioning

confidence: 99%

“…61 In addition, L1 cell adhesion molecule (L1CAM) expression has not been reported in PeM 66,67 whereas the expression of this immunomarker is seen in a subset of ATs and WDPMTs. 67 Emerging Markers to Distinguish Peritoneal Mesothelioma From Reactive Mesothelial Hyperplasia Loss of 5-hydroxymethylcytosine (5-hmC) in > 50% of tumor nuclei has been found in 58% of PeMs (surgical specimens, unpublished series). 68 This percentage contrasts with the loss of this immunomarker in 30% of biopsy specimens and 40.6% of cell blocks in another study.…”

Section: Immunohistochemical Featuresmentioning

confidence: 99%

See 4 more Smart Citations

Peritoneal Mesothelioma—An Update

Malpica¹

2022

Advances in Anatomic Pathology

View full text Add to dashboard Cite

A remarkable amount of new information has been generated on peritoneal mesothelioma (PeM), ranging from nomenclature changes, including the removal of “malignant” when referring to this neoplasm and the use of the term “tumor” rather than “mesothelioma” to designate the neoplasm formerly known as “well-differentiated papillary mesothelioma”, to the acknowledgment that PeMs can be associated with tumor predisposition syndromes or germline mutations. Although the disease is still more frequently seen in caucasian males, PeM is not uncommon in women. In addition, it can represent a diagnostic challenge when it has an uncommon presentation (ie, paraneoplastic syndrome or incidental finding) or when it has confounding histologic features. Ancillary testing, including immunohistochemical stains, in situ hybridization for CDKN2A or NF2, and molecular studies, in selected cases, allows its correct diagnosis. The molecular landscape of PeM is still a work in progress; however, some findings, such as ALK gene rearrangements and EWSR1/FUS-ATF1 fusions, are specifically seen in PeM of young patients. The biological behavior of PeM is variable; however, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have markedly improved the survival of patients affected by this disease.

show abstract